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Abstract
Line-1, a weakly immunogenic lung tumor cell line derived from the BALB/c mouse, metastasizes spontaneously to the
lungs of mice following subcutaneous administration. The parameters that influence metastasis as well as the progression
of metastatic lung disease following surgical resection of primary subcutaneous tumors were characterized. Histological
analysis of the lungs obtained from mice bearing different size subcutaneous tumors demonstrated that >90% of the mice
developed micrometastatic disease in the lungs when the tumor exceeded 650 mm3 in size. Surgical resection of subcu-
taneous tumors resulted in the cure of primary disease in 95% of the mice. Macroscopic tumor nodules were grossly visible
in the lungs of 75% of the mice 5 weeks after surgery. Serum amyloid A level correlated with primary tumor burden and
was diagnostic for the presence of metastatic disease. The efficiency of metastasis, post-surgical primary tumor recurrence
and long-term survival were significantly different between BALB/c mice obtained from different suppliers. The Line-1-
BALB/c surgical metastasis model provides a clinically relevant tool for the evaluation of anti-cancer therapies, especially
those that are designed to target long-term suppression of minimal residual disease following surgical intervention.
Introduction
Whereas studies with syngeneic transplantable murine tu-
mor models have contributed greatly to our understanding
of tumor biology and therapy, the majority of such studies
have been performed in mice with localized disease. In the
clinical setting however, most primary tumors can be cured
by surgery but patients eventually succumb to metastatic
disease. Therefore, the development of clinically relevant
metastatic tumor models is critical to the identification of
treatment protocols that are effective in patients. Since most
tumor cell lines do not spontaneously metastasize, meta-
stasis is generally induced by intravenous injection of tumor
cells in transplantable murine tumor models. However, the
relevance of intravenous metastasis models to spontaneously
metastasizing disease is yet to be determined. Several trans-
plantable tumor cell lines that spontaneously metastasize
from a subcutaneous site to different organs have been de-
scribed [1–4]. With few exceptions [4], these models have
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not been characterized in detail and their use has been
limited.
Line-1 is a weakly immunogenic tumor cell line that
was derived from a spontaneously arising lung alveolar
carcinoma of the BALB/c mouse [2]. When injected subcu-
taneously, Line-1 cells grow rapidly and metastasize spon-
taneously to the lungs [2]. The metastatic nature of this
cell line is associated with low Class I MHC expression,
which is inducible by interferon-gamma (IFNγ ) or dimethyl
sulfoxide (DMSO) [5]. Line-1-BALB/c model has been util-
ized to investigate the role of cytotoxic T-cells and natural
killer (NK) cells as well as the involvement of the tran-
scription factor nuclear factor kappa B (NF-κB) in tumor
metastasis [6, 7]. Several cancer immunotherapy proto-
cols including cytokine-based therapies [8, 9], gene-therapy
based approaches involving co-stimulatory molecules [10]
and suicide genes [11] have also been evaluated in this
system.
While the metastatic properties of Line-1 cells are well
established, the Line-1-BALB/c spontaneous metastasis
model has not been utilized to evaluate strategies targeting
disseminated disease. To this end, we recently developed
a surgical embodiment of this model to test the anti-tumor
efficacy of a tumor immunotherapy protocol [12, 13]. In this
model, primary subcutaneous Line-1 tumors are induced and
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are allowed to metastasize to the lungs of mice. Treatment
is then administered either prior to or after surgical debulk-
ing of the primary tumor, and primary tumor recurrence as
well as the progression of metastatic disease is monitored.
Here we describe this clinically relevant model which was
designed for the evaluation of adjuvant therapies for the
treatment of disseminated disease.
Methods
Mice and cell lines
Female BALB/c mice at six to eight weeks of age were ob-
tained either from Jackson Laboratories (Bar Harbor, Maine)
or from Taconic Laboratories (Germantown, New York).
Mice were maintained five per cage under standard hous-
ing conditions. Animals were used in the studies at 8–12
weeks of age. Line-1 (a BALB/c lung alveolar carcinoma
cell line) was a gift from Dr John G. Frelinger (University
of Rochester, School of Medicine and Dentistry, Rochester,
New York).
Tumor cell injections
Mice were injected subcutaneously behind the neck just
above the scapula with 1×107 tumor cells (in 200 µl saline).
Tumor growth was monitored by measurement of tumor dia-
meter with engineer’s calipers twice a week. Tumor volume
was determined by the formula a × b2/2 where a and b are
the longest and the shortest perpendicular diameters of the
tumor, respectively. When the tumors reached the desired
size (250–1500 mm3) the mice underwent surgery or were
sacrificed and evaluated for metastasis. Only mice with cir-
cular/oblong tumors were included in the studies. Animals
with irregular tumors were not used due to imprecise tumor
volume determination.
Surgery
All surgical procedures were performed in a laminar flow
surgical hood under aseptic conditions. Surgical instruments
were sterilized by autoclaving and personnel wore dispos-
able sterile gown, mask, head cover and gloves. Mice were
injected intra-peritoneally with Avertin (0.012 ml/g weight)
to achieve a surgical phase of anesthesia and were placed
on a sterile surgical diaper over a heated circulating water
mat to maintain body warmth. The skin around the subcu-
taneous tumor was shaved, scrubbed with antiseptic soap,
prepared with alcohol and painted with betadine. A skin in-
cision was made over the circumferential length of the tumor
with micro-dissection scissors and tumor tissue was isolated
by sharp dissection. Hemostasis was established by gentle
pressure or electrocautery of the major vessels entering into
the tumor tissue. The isolated tumor tissue was removed and
the skin was closed with simple interrupted sutures using
monofilament 6-0 nylon or 6-0 vicryl. Mice were injected
i.p. with 0.2 ml of sterile saline, kept warm and observed
until they recovered from anesthesia. When fully recovered
they were returned to their respective cages. The entire sur-
gery lasted 10 to 15 min per mouse. Marcaine (50% solution)
was topically applied to the wound 3 times a day for 2 days
to reduce post-surgical discomfort.
Analysis of micrometastatic disease
Mice bearing different size tumors (or at different time
points after surgery) were sacrificed by CO2 inhalation, the
lungs were removed, rinsed with saline and fixed in 10%
formalin. Formalin-fixed lungs were embedded in paraffin
and serial sections (5 µm thick) were cut throughout the
entire lung tissue. Every 25th section was saved and stained
with hematoxylin and eosin (H & E) using standard proced-
ures. H & E stained lung sections were analyzed for tumor
microscopically under 40× and 100× magnification. Tumor
nodules were identified as densely packed large mitotic cells
staining strongly with eosin against the normal lung tissue
background.
Analysis of macrometastatic disease
Mice bearing different size tumors (or at different time
points after surgery) were sacrificed by CO2 inhalation, the
lungs were removed and were stained with India ink as pre-
viously described [14]. White tumor nodules against a black
lung background were counted under a dissecting micro-
scope. Tumor area was determined using the formula πab/2,
where a and b are the shortest and longest perpendicular
dimensions of the tumor nodule.
Quantification of serum TNFα, IL-1β and SAA
Serum TNFα, IL-1β and amyloid A levels were determ-
ined using the murine TNFα (Endogen, Rockford, Illinois),
IL-1β (Endogen) and SAA-specific (Biosource, Camarillo,
California) ELISA kits as recommended by the manufac-
turer.
Long-term survival studies
Mice were injected with tumor cells and primary tumors
were allowed to reach an average size of 1000 mm3. They
were then surgically resected as described above and mice
were monitored for primary tumor recurrence and signs of
systemic disease. Animals were sacrificed at the first sign of
dyspnea, paralysis or cachexia.
Statistical methods
Student’s t-test (unpaired) was utilized to determine the sig-
nificance of the differences between groups in macrometa-
stasis studies as well as in SAA analyses. Linear regression
analysis was used to determine the correlation coefficients
for tumor volume vs weight, and SAA concentration vs
primary tumor volume (Stata SE/8.2, Stata Corp., College
Station, Texas). Receiver-operator characteristic analysis
was employed to determine the significance of selected SAA
threshold concentrations as diagnostic for micrometastatic
disease (Stata SE/8.2, Stata Corp., College Station, Texas).
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Figure 1. Calculated primary tumor volume versus actual weight. Subcu-
taneous tumors were induced and allowed to reach different sizes. Tumor
volume was determined for each mouse as described in the methods. The
mice were sacrificed, tumors were removed and weighed. Tumor volume
was then plotted against actual tumor weight for each individual (n = 35).
Linear regression analysis demonstrated that the correlation between tumor
volume and weight was highly significant (r = 0.793, P = 0.0001).
Table 1. Lung micrometastasis in the Line-1-BALB/c spontan-
eous tumor metastasis model.
Primary tumor Micrometastasis
Size (mm3) Days % of mice % of sections
259 ± 15 10.8 ± 1.8 80 (4/5) 34 (10/29)
642 ± 86 14.6 ± 3.6 100 (5/5) 62 (21/34)
1105 ± 180 16.6 ± 2.7 100 (4/4) 72 (18/25)
The significance of the differences between survival pat-
terns was determined by log-rank analysis (GraphPad Prism,
GraphPad Software, Inc., San Diego, California).
Results
Characterization of lung metastasis
We initially attempted to establish the minimum primary tu-
mor size and/or growth period required to achieve consistent
metastasis to the lungs. In most studies, subcutaneous tu-
mor growth is monitored by measurement of tumor diameter.
However, measurement of tumor diameter is not always
straightforward and the formulas that are used to determine
volume based on these measurements may not necessarily
be accurate. To determine whether the formula we used
reflected the tumor size accurately, we compared the calcu-
lated tumor volume to tumor weight. Subcutaneous tumors
were induced, allowed to reach different sizes, measured
and then surgically resected and weighed. The calculated tu-
mor volume was then plotted against weight. The results are
shown in Figure 1. These data establish that our formula for
estimating tumor volume reflected the actual tumor size ac-
curately and thus could be used to determine the relationship
between primary tumor size and efficiency of metastasis.
The relationship between primary tumor size and meta-
stasis kinetics was investigated by histological analysis of
the lungs in mice bearing primary tumors of different sizes.
Mice were injected with Line-1 cells subcutaneously and tu-
mors were monitored until they reached an average of 250,
650 and 1100 mm3 in size. The mice in each group were
then sacrificed, the lungs were removed and histological sec-
tions were prepared from each lung. Histological sections
obtained throughout the lung were analyzed for evidence
of metastatic tumor nodules by microscopic examination
of each section. The results are summarized in Table 1.
While few small lesions were observed in mice bearing small
(250 mm3) primary tumors, most sections were found to
be tumor-free (Table 1). In mice bearing primary tumors
that were 650 mm3 on average, however, metastatic nod-
ules were more easily distinguishable and numerous. In fact
lungs from all mice in this group were positive for metastasis
and the majority of the sections (62%) showed evidence of
tumor. In mice bearing larger tumors, metastatic nodules
were not larger in size but the percentage of lung sections
that were positive for metastasis was slightly higher (72%,
Table 1). The average size of primary tumors correlated well
with time of tumor growth in this study (Table 1). These res-
ults establish that while evidence of micrometastatic disease
can be found in the lungs of mice bearing primary tumors
as small as 250 mm3, development of multi-focal, well-
established disease is achieved only when the primary tumor
exceeds 650 mm3 in size.
The primary goal of this study was to develop a model
that could be utilized to evaluate adjuvant anti-cancer
strategies in combination with surgery. To this end, the pro-
gression of metastatic disease after surgical removal of the
primary tumor was evaluated. Subcutaneous tumors were
induced and were allowed to reach ∼1000 mm3 in size to
ensure efficient metastasis to the lungs. Primary tumors were
then resected and the post-surgical progression of meta-
static lung tumors was monitored by histological analysis
of lungs 7, 14 and 21 days after surgery. Representative
lung sections from mice with efficient metastasis and the
results of microscopic analyses of the lungs are shown in
Figure 2 and Table 2, respectively. While the percentage
of tumor-positive lung sections remained unchanged after
surgery (Table 2), metastatic tumors grew rapidly and nor-
mal lung tissue was progressively replaced by tumor in
individuals with established micrometastasis (Figure 2). Ap-
proximately 15% (2/14) mice were found to be free of lung
tumors histologically in this study indicating that metastasis
is not 100% efficient even when the primary tumor is as
large as 1000 mm3 (Table 2). Overall, combined results
from Tables 1 and 2 show that when the primary tumor ex-
ceeds 650 mm3 in size, >90% (21/23) of the mice develop
micrometastatic lung disease.
Although the histological characterization of micro-
scopic disease provided valuable data on the kinetics of
metastasis and the post-surgical growth pattern of lung tu-
mors, microscopic analysis of metastatic lung tumors as
a way of monitoring disease progression is labor intens-
ive and expensive. A simpler approach, which is used in
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Figure 2. Post-surgical growth of lung micrometastases. Primary tumors were allowed to grow to a size of 1075 ± 199 mm3 and were surgically removed.
Mice were sacrificed either on the day of surgery, or 7, 14 and 21 days after surgery, and the lungs were analyzed microscopically for tumor burden as
described in the methods. The micrographs shown are representative for each time point. ‘T’ indicates tumor tissue (n = 5, magnification = 40×).
Table 2. Post-operative Lung micrometastasis in the Line-1-BALB/c
spontaneous tumor metastasis model.
Post-operative daya % of mice positive % of sections positive
7 75 (3/4) 58 (30/52)
14 100 (5/5) 69 (33/48)
21 80 (4/5) 63 (38/60)
aAverage primary tumor size at time of surgery was 1075 ± 199 mm3.
the majority of published studies, involves the analysis of
the number and/or size of macroscopic lung tumors. In the
studies described above (Table 1), macroscopic tumor nod-
ules were observed in some of the mice bearing primary
tumors ≥650 mm3 in size. Moreover, post-surgical analysis
of lung sections demonstrated that metastatic lung tumors
progressed rapidly after the resection of the primary tumor
(Figure 2) and that tumor nodules were macroscopically
visible by three weeks after surgery in the lungs of most
animals. To determine whether the macroscopic lung tu-
mor nodule numbers could be used as a quantitative marker
for post-surgical disease progression, we analyzed the lungs
of mice at 1, 3 and 5 weeks after surgical removal of the
primary tumor (890 ± 240 mm3). At week 1 mice had an
average of 0.7 ± 1.1 macroscopic lung tumors (n = 10).
At weeks 3 and 5, the average number of lung tumors were
3.8±3.5 and 3.5±3.8 nodules per lung, respectively (n = 8
for both groups). The differences between week 1 and weeks
3 or 5 were statistically significant (P < 0.04). There was no
difference between weeks 3 and 5 (P = 0.89). Thus, short-
term tumor growth could be monitored by macroscopic
analysis of the lungs between weeks 3–5 post-surgery. In
these studies variation in both tumor number [1–10] and
size (0.2–4 mm) was observed between individual mice in
several independent studies (data not shown). The large
standard deviations within each group were in part due to
this variation as well as the presence of several mice that
were free of macroscopic disease (25%, 4/16).
Serum amyloid A as an indirect tumor marker
The studies described above demonstrate that quantification
of macroscopic lung tumor burden can provide a simple
method for evaluating the efficacy of a given treatment in
the Line-1-BALB/c model. On the other hand, this approach
requires that the mice are sacrificed at a selected time-point.
The identification of a soluble tumor marker that can be
detected in the serum would provide the ability to monitor
tumor burden continuously without sacrificing the mice. In
addition, such a marker can be used as a diagnostic tool to
identify mice with poor vs efficient metastasis prior to treat-
ment thus possibly reducing the variability caused by the
differences in pre-treatment tumor burden among individual
mice. Serum protein biomarkers have been identified for
several human cancers [15]. However, similar endogenous
tumor markers are not currently available for murine tumor
models.
Human serum amyloid A (SAA), an acute phase liver
protein which is produced rapidly in response to inflammat-
ory stimuli, has been shown to correlate with disease stage
and prognosis in cancer patients [16–18]. The correlation
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Figure 3. SAA level versus tumor burden. A. Mice with large subcutaneous
tumors (1581 ± 248 mm3) or that were tumor-free were bled and serum
SAA, TNFα and IL-1β levels were determined. Bars = standard devi-
ation, n = 3 per group. B. Primary tumors were induced and allowed
to grow to selected sizes (n = 6, 11, 10, 11 and 7 for naïve mice,
and mice with average tumor sizes of 286 mm3, 695 mm3, 1057 mm3,
1473 mm3, respectively). SAA levels were determined for each individual
and the average SAA concentration for each size group was plotted against
the corresponding tumor group. Linear regression analysis demonstrated
a significant correlation between tumor size and SAA level (r = 0.523
with a P -value of 0.0006). C. Subcutaneous tumors were induced, allowed
to grow to different sizes (555–1879 mm3) and were removed surgically.
Serum was collected from each individual 5 weeks after surgery and the
mice were sacrificed. Macroscopically visible total lung tumor area was
determined for each individual and plotted against SAA values for each
individual. Linear regression analysis did not show a significant correlation
between metastatic tumor area and SAA level (r = 0.406 with a P -value
of 0.133). Receiver-operator characteristic (ROC) analysis demonstrated a
significant predictive threshold for an SAA concentration of ≥0.05 ng/ml
and the presence of metastatic lung disease (ROC area of 0.818 with a 95%
confidence interval between 0.58 and 1.0).
between SAA and tumor burden has not been investig-
ated in murine tumor models. To determine whether SAA
levels correlated with tumor presence in the Line-1-BALB/c
model, serum SAA levels in tumor-bearing and naïve mice
were measured. The changes in the serum levels of the in-
flammatory cytokines IL1β and TNFα, which have been
shown to induce SAA expression in response to inflammat-
ory stimuli [19], were also determined. The results shown in
Figure 3A demonstrate that tumor-bearing mice have elev-
ated levels of SAA in their sera in comparison to naïve mice.
On the other hand, no increases in IL-1β or TNFα could
be detected in the sera of mice with established tumors as
compared to tumor-free naïve mice.
To determine whether the serum SAA levels correlated
with tumor burden in our model, we measured both primary
tumor size and serum SAA levels in individuals with dif-
ferent size subcutaneous tumors. The average SAA level
was then plotted against average tumor size for each size
group. The results are shown in Figure 3B. These results
demonstrate that average serum SAA levels increased with
increasing tumor size. While the SAA levels within each
group displayed considerable variability (Figure 3B), the
correlation between primary tumor size and SAA level was
significant (Figure 3, legend).
Finally we examined whether the post-surgical SAA
levels correlated with metastatic tumor burden in the lungs.
Primary tumors were allowed to grow to an average size
of 1000 mm3 and then were surgically resected. The SAA
levels remained high within the first 3–4 days after surgery
due possibly to surgical trauma but then decreased to near
background levels by day 7 (data not shown). Five weeks
after surgery, blood was collected, the mice were sacrificed
and lung tumor burden was quantified. Lung tumor burden
(total tumor surface area) was then plotted against serum
SAA level for each mouse. The results are shown in Fig-
ure 3C. Whereas the correlation between lung tumor burden
and SAA level was not statistically significant (Figure 3, le-
gend), an SAA level of >0.05 ng/ml was predictive for the
presence of metastatic lung tumors (Figure 3, legend). Thus
SAA is more useful as a diagnostic (tumor vs no tumor) than
a quantitative marker for metastatic disease in this model.
Efficiency of metastasis in BALB/c mice obtained from
different suppliers
The above studies were performed with BALB/c mice that
were obtained from Jackson laboratories. In separate studies
we also tested BALB/c mice from Taconic laboratories and
noticed that Line-1 tumors metastasized more aggressively
in the Taconic BALB/c. To determine if this preliminary
observation was valid, we decided to compare the pattern
of metastasis in mice that were obtained from Jackson vs
Taconic laboratories. Primary subcutaneous tumors were in-
duced, allowed to grow to an average size of 750 mm3,
and were then surgically resected. Mice were sacrificed five
weeks after surgery and macroscopic lung tumor burden was
quantified. BALB/c mice that were obtained from Jackson
laboratories had an average of 1.6 ± 3.4 tumors/lung while
the Taconic mice had 5.5 ± 4.2 tumors/lung (n = 8 per
group, P = 0.035), confirming the preliminary observation
that Line-1 cells metastasized more efficiently in the Taconic
BALB/c mice.
All prior studies addressed the short-term kinetics (up to
five weeks) of lung metastasis in the Line-1-BALB/c model.
We next evaluated the post-surgical survival patterns for
both Taconic and Jackson Laboratory mice to determine the
long-term growth kinetics of metastatic disease. The results
are shown in Figure 4. The data demonstrate that mice in
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Figure 4. Post-surgical survival in BALB/c mice obtained from different
sources. Primary tumors were induced and were surgically removed upon
reaching an average size of 997±168 mm3 for Jackson and 1011±188 mm3
for Taconic mice. Mice were then monitored for long-term survival (n = 20
per group). The difference between the two groups was significant at 6
weeks, but not at 12 weeks as determined by log-rank analysis (P = 0.012
and 0.055, respectively).
each group began dying of metastatic tumors within three
to four weeks of surgery. Death from metastatic disease
occurred more rapidly in the Taconic mice, with a median
survival of 4.5 weeks as compared to 8 weeks for the Jackson
mice. By week 12 post-surgery, 75% of the Taconic mice
had died from metastatic disease as compared to 55% of
the Jackson mice. Primary tumor recurrence during the 12-
week post-surgical period was also significantly higher in
the Taconic BALB/c (30%, 6/20) as compared to Jackson
BALB/c (5%, 1/20). These results confirm that Line-1 cells
metastasize more aggressively in the BALB/c mice obtained
from Taconic Laboratories as compared to those purchased
from Jackson Laboratories. The data also demonstrate that
metastatic disease, once established, progresses rapidly, and
that most mice die from lung tumors within eight weeks of
surgery.
Discussion
The studies described here establish that the Line-1-BALB/c
spontaneous metastasis model provides a reliable system for
the evaluation of anti-cancer strategies, especially those that
target post-surgical micrometastatic disease. The availability
of such a model is particularly relevant to immunothera-
peutic strategies, an approach which is now recognized as
most effective in the minimal residual disease setting [20].
It is expected that the information provided here will expand
the use of this model among cancer investigators.
Whereas the above studies demonstrated the utility of the
Line-1-BALB/c surgical metastasis model, they also identi-
fied some of its limitations. For example, although the great
majority (90%) of the mice developed micrometastases in
the lung once the average size of the primary tumor exceeded
650 mm3, micrometastatic lesions progressed to macro-
scopic disease in 75% of these mice. This is not surprising
as studies by others have demonstrated that only a subset
of micrometastases persist to form vascularized macrometa-
static nodules [21]. In addition, we found that metastasis
was less efficient and variability was more pronounced in
the Jackson Laboratory mice as compared to the Taconic
Laboratory mice. Both the short-term development pattern
of lung tumors and long-term post-surgical survival of mice
(Figure 4) demonstrate that BALB/c mice obtained from
Taconic laboratories are more susceptible to Line-1 meta-
stasis. It is well established that different strains of mice
react dissimilarly to immune challenge due to genetic vari-
ability [22]. On the other hand, such differences would not
be expected, or should be minimal, within the same inbred
strain. One possible explanation for the observed differences
between the Jackson and the Taconic BALB/c is genetic
drift. Intra-strain genetic drift can occur if populations re-
main segregated for extended periods [23]. Our data support
the notion that genetic drift between the BALB/c colonies of
Jackson and Taconic laboratories has reached a level where
it can impact physiological responses differentially, result-
ing in significant experimental variability. The higher rate
of metastasis, lower variability and more aggressive post-
surgical metastatic disease progression in Taconic BALB/c
suggests that this substrain should be preferred in future
studies.
A potentially valuable finding in this study was the
demonstration that serum SAA levels increase in tumor-
bearing mice. Analysis of SAA levels in mice with increas-
ing primary tumor burden showed that SAA correlated with
tumor burden and could be used as a marker for monitoring
tumor progression (Figures 3A and B). However, SAA level
in post-surgical mice with macroscopic lung tumors did not
correlate with metastatic tumor burden quantitatively, but
instead was indicative of tumor absence or presence. The
relatively low metastatic tumor burden in post-surgical mice
may not induce sufficient inflammatory activity thus making
it difficult to use SAA as a quantitative marker in this set-
ting. This notion is supported by the very low/background
levels of SAA found in mice bearing small primary tumors
(≤250 mm3, Figure 3B). On the other hand, the results
shown in Figure 3C demonstrate that SAA can still be useful
as a diagnostic marker for metastatic disease in post-surgical
mice. Whether this finding applies to other murine tumor
models remains to be determined.
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